{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"TPST","limit":50},"count":50,"signals":[{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"to advance pivotal development. Our second small-molecule product candidate is TPST-1495, which we plan to initiate a Phase 2 study for in familial adenomatous polyposis (FAP), with first patient enrollment expected in 2026. The study is expected to be funded by the National Cancer Institute (NCI) and conducted through the Cancer Prevention Clinical Trials Network (CP-CTNet), enabling advancement wit","filed_date":"2026-03-30","accession":"0001193125-26-130490","full_text":"https://origin.rootz.global/static/filing/0001193125-26-130490.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":81,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2026-03-30","accession":"0001193125-26-130490","full_text":"https://origin.rootz.global/static/filing/0001193125-26-130490.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":43,"context":"r of the Board |  2021 |  | |  Christine Pellizzari |  58 |  Director |  2021 |  | |  Michael Raab(2) |  61 |  Director |  2021 |  | |  Ronit Simantov |  61 |  Director |  2021 |  | (1) Dr. Angel was appointed as the Companys Chief Executive Officer, President and director, effective immediately following the Closing of the Asset Acquisition. (2) Mr. Raab, Chair of the Board since 2021, in light of his other professional commit","filed_date":"2026-03-30","accession":"0001193125-26-130490","full_text":"https://origin.rootz.global/static/filing/0001193125-26-130490.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"te shall have the meaning ascribed to such term in Section 4.1(c).  Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.  Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b).  Material Permits shall have the meaning ascribed to such term in Section 3.1(n).  Per Share Purchase Price equals $2.16, subject to ad","filed_date":"2026-03-23","accession":"0001193125-26-118618","full_text":"https://origin.rootz.global/static/filing/0001193125-26-118618.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":37,"context":"#TOC) and policies of employee compensation as they relate to risk management and risk-taking incentives, to determine whether such compensation policies and practices are reasonably likely to have a material adverse effect on us, including whether our incentive compensation plans encourage excessive or inappropriate risk taking. Our Nominating and Corporate Governance Committee monitors the effectiveness of our corpora","filed_date":"2025-12-31","accession":"0001140361-25-047054","full_text":"https://origin.rootz.global/static/filing/0001140361-25-047054.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":59,"context":"ClassI nominee, Geoff Nichol, to the Board of Directors to hold office until the 2028Annual Meeting of Stockholders; | | | 2. | To approve, on an advisory basis, the compensation paid to the Companys named executive officers, as disclosed in this proxy statement; | | | 3. | To ratify the selection of Ernst& Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December3","filed_date":"2025-12-31","accession":"0001140361-25-047054","full_text":"https://origin.rootz.global/static/filing/0001140361-25-047054.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"laboration Agreement.  Program Know-How means Know-How that is: (a) Controlled by either Seller at the Closing Date; and (b) directed to the Development or commercialization of the Programs.  Program Material Adverse Effect means any event, change, circumstance, occurrence, effect, result or state of facts that, individually or in the aggregate, has, or would reasonably be expected to have, a material adverse effect on","filed_date":"2025-11-19","accession":"0001193125-25-287163","full_text":"https://origin.rootz.global/static/filing/0001193125-25-287163.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":51,"context":"ny litigation or other legal proceedings are uncertain, we are not currently a party to any material legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, financial position, results of operations or cash flows. Item 1A. Risk Factors Our business involves significant risks, some of which are described below. You should carefully consid","filed_date":"2025-11-05","accession":"0001193125-25-265946","full_text":"https://origin.rootz.global/static/filing/0001193125-25-265946.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":49,"context":"ny litigation or other legal proceedings are uncertain, we are not currently a party to any material legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, financial position, results of operations or cash flows. Item 1A. Risk Factors Our business involves significant risks, some of which are described below. You should carefully consid","filed_date":"2025-08-11","accession":"0000950170-25-106558","full_text":"https://origin.rootz.global/static/filing/0000950170-25-106558.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"ts shall have the meaning ascribed to such term in Section 3.1(p).  Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.  Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b).  Material Permits shall have the meaning ascribed to such term in Section 3.1(n).  Per Share Purchase Price equals $6.25, subject to ad","filed_date":"2025-06-12","accession":"0001193125-25-139899","full_text":"https://origin.rootz.global/static/filing/0001193125-25-139899.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":49,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2025-05-13","accession":"0000950170-25-070441","full_text":"https://origin.rootz.global/static/filing/0000950170-25-070441.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":35,"context":"nformation for each of the last two completed fiscal years regarding compensation awarded to or earned by our Chief Executive Officer and the two other most highly compensated executive officers (the Named Executive Officers) during the fiscal years indicated:  |  | |  Name and Principal Position |  |  Year |  |  |  Salary$ |  |  |  OptionAwards($)(1)(2) |  |  |  Non-EquityIncentive PlanCompensation($)(3) |  |  |  All O","filed_date":"2025-04-30","accession":"0001193125-25-107127","full_text":"https://origin.rootz.global/static/filing/0001193125-25-107127.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":76,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2025-03-27","accession":"0000950170-25-046144","full_text":"https://origin.rootz.global/static/filing/0000950170-25-046144.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2024-11-12","accession":"0000950170-24-125499","full_text":"https://origin.rootz.global/static/filing/0000950170-24-125499.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2024-08-08","accession":"0000950170-24-094124","full_text":"https://origin.rootz.global/static/filing/0000950170-24-094124.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2024-05-09","accession":"0000950170-24-057072","full_text":"https://origin.rootz.global/static/filing/0000950170-24-057072.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":58,"context":"aab and Ronit Simantov, to the Board of Directors to hold office until the 2027 Annual Meeting of Stockholders; | | |  |  2. |  To approve, on an advisory basis, the compensation paid to the Companys named executive officers, as disclosed in this proxy statement; | | |  |  3. |  To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending Dec","filed_date":"2024-04-23","accession":"0001193125-24-106959","full_text":"https://origin.rootz.global/static/filing/0001193125-24-106959.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":75,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2024-03-19","accession":"0000950170-24-033555","full_text":"https://origin.rootz.global/static/filing/0000950170-24-033555.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2023-11-08","accession":"0000950170-23-061278","full_text":"https://origin.rootz.global/static/filing/0000950170-23-061278.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2023-08-10","accession":"0000950170-23-041429","full_text":"https://origin.rootz.global/static/filing/0000950170-23-041429.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2023-05-10","accession":"0000950170-23-020579","full_text":"https://origin.rootz.global/static/filing/0000950170-23-020579.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":57,"context":"ther items, increase the total number of shares of our common stock issuable thereunder by 1,150,000 shares; | | |  |  3. |  To approve, on an advisory basis, on the compensation paid to the Companys named executive officers, as disclosed in this proxy statement; and | | |  |  4. |  To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending","filed_date":"2023-05-01","accession":"0001193125-23-130398","full_text":"https://origin.rootz.global/static/filing/0001193125-23-130398.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2023-03-22","accession":"0000950170-23-009237","full_text":"https://origin.rootz.global/static/filing/0000950170-23-009237.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2022-11-08","accession":"0001544227-22-000006","full_text":"https://origin.rootz.global/static/filing/0001544227-22-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2022-08-15","accession":"0001628280-22-022788","full_text":"https://origin.rootz.global/static/filing/0001628280-22-022788.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":42,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2022-05-13","accession":"0001628280-22-014231","full_text":"https://origin.rootz.global/static/filing/0001628280-22-014231.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"e in the Amended 2019 ESPP.  **Participation in the Amended 2019 ESPP** An eligible employee may enroll in the Amended 2019 ESPP by delivering to us, within the time specified in the offering, an enrollment form authorizing contributions which may not exceed the maximum amount specified by the Plan Administrator (but which in no event may exceed 15% of such employees earnings (as determined by the Pl","filed_date":"2022-05-02","accession":"0001193125-22-136738","full_text":"https://origin.rootz.global/static/filing/0001193125-22-136738.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":19,"context":"irectors are elected by a plurality of the votes cast at the Annual Meeting by the holders entitled to vote on the election of directors. Accordingly, the nominee receiving the most FOR votes will be elected as a director. Abstentions will have no effect on the outcome of Proposal 1. You may not vote your shares cumulatively for the election of directors. Shares represented by executed proxies will be voted, if author","filed_date":"2022-05-02","accession":"0001193125-22-136738","full_text":"https://origin.rootz.global/static/filing/0001193125-22-136738.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":43,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2022-03-29","accession":"0001628280-22-007717","full_text":"https://origin.rootz.global/static/filing/0001628280-22-007717.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"ctors, senior management, or operational personnel; our ability to integrate TempestTx, Inc. and Millendo Therapeutics, Inc. (now the Company) successfully and realize the anticipated benefits of the merger of the two entities, which closed in July 2021; our expectation regarding the period during which we will qualify as a smaller reporting company under the federal securities laws: our ability to develop","filed_date":"2022-03-29","accession":"0001628280-22-007717","full_text":"https://origin.rootz.global/static/filing/0001628280-22-007717.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":43,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2021-11-10","accession":"0001628280-21-022803","full_text":"https://origin.rootz.global/static/filing/0001628280-21-022803.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":43,"context":"y of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2021-08-12","accession":"0001193125-21-244745","full_text":"https://origin.rootz.global/static/filing/0001193125-21-244745.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"sider the risks described below, as well as general economic and business risks and the other information in this Annual Report on Form 10-K. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have mad","filed_date":"2021-03-29","accession":"0001544227-21-000018","full_text":"https://origin.rootz.global/static/filing/0001544227-21-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K. | | | | | | | | EXPLANATORY NOTE On December7, 2018, OvaScience, Inc., or the Company, completed a reverse merger with what was then known as Millendo Therapeutics,Inc., or PrivateMillendo, in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated as of August8, 2018, as amended on Sep","filed_date":"2021-03-29","accession":"0001544227-21-000018","full_text":"https://origin.rootz.global/static/filing/0001544227-21-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"2020 or (ii) the Board's approval of the achievement of certain performance criteria; and 2) one twelfth (1/12th) of the remaining shares subject to this option grant will vest in equal monthly installments thereafter. 17 [Table of Contents](#i5e3354874b4b44c4b1e2b472c7b1219a_7) The following table summarizes the activity related to stock option grants to employees and nonemployees for the nine mont","filed_date":"2020-11-09","accession":"0001544227-20-000045","full_text":"https://origin.rootz.global/static/filing/0001544227-20-000045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"lly to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Companys business, financial condition, results of operations and growth prospects. In addition, the Company is subject to other challenges and risks specific to its business and its ability t","filed_date":"2020-11-09","accession":"0001544227-20-000045","full_text":"https://origin.rootz.global/static/filing/0001544227-20-000045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"2020 or (ii) the Board's approval of the achievement of certain performance criteria; and 2) one twelfth (1/12th) of the remaining shares subject to this option grant will vest in equal monthly installments thereafter. 16 [Table of Contents](#icfadc7b0e2d84461b4e12809b5f28b23_7) The following table summarizes the activity related to stock option grants to employees and nonemployees for the six month","filed_date":"2020-08-10","accession":"0001544227-20-000039","full_text":"https://origin.rootz.global/static/filing/0001544227-20-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"lly to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Companys business, financial condition, results of operations and growth prospects. In addition, the Company is subject to other challenges and risks specific to its business and its ability t","filed_date":"2020-08-10","accession":"0001544227-20-000039","full_text":"https://origin.rootz.global/static/filing/0001544227-20-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"rience, a disruption or delay in our ability to enroll and assess patients. As the COVID-19 pandemic continues, we anticipate an impact on our ability to initiate trial sites and maintain patient enrollment. We could also see an impact on our ability to acquire supplies of study drug, report trial results or interact with regulators, ethics committees or other important agencies due to limitations in","filed_date":"2020-05-08","accession":"0001544227-20-000014","full_text":"https://origin.rootz.global/static/filing/0001544227-20-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"lly to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Companys business, financial condition, results of operations and growth prospects. In addition, the Company is subject to other challenges and risks specific to its business and its ability t","filed_date":"2020-05-08","accession":"0001544227-20-000014","full_text":"https://origin.rootz.global/static/filing/0001544227-20-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":41,"context":"f Ernst YoungLLP as the independent registered public accounting firm of the Company for its fiscal year ending December31, 2020. 3.To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement. 4.To conduct any other business properly brought before the Annual Meeting. These items of business are more fully described in the Proxy Statement","filed_date":"2020-04-24","accession":"0001544227-20-000008","full_text":"https://origin.rootz.global/static/filing/0001544227-20-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"nts with CAH in March 2018 and initiated a Phase 2b trial in the third quarter of 2018. We expect to report topline results from the first cohort of the Phase 2b trial in the second half of 2020. Enrollment for the second cohort of the Phase 2b trial is continuing and sites are actively enrolling patients. We expect to provide an additional update on the second cohort in the second half of 2020. We a","filed_date":"2020-03-11","accession":"0001544227-20-000004","full_text":"https://origin.rootz.global/static/filing/0001544227-20-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"ral economic and business risks and the other information in this Annual Report on Form 10-K. The occurrence of any of the events or circumstances described below or other adverse events could have a material adverse effect on our business, results of operations and financial condition and could cause the trading price of our common stock to decline. Additional risks or uncertainties not presently known to us or that we","filed_date":"2020-03-11","accession":"0001544227-20-000004","full_text":"https://origin.rootz.global/static/filing/0001544227-20-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"s of each jurisdiction which requires such qualification, except where the failure to be so qualified or in good standing would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the condition (financial or otherwise), prospects, earnings, business or properties of the Company and its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary","filed_date":"2020-03-04","accession":"0001104659-20-028925","full_text":"https://origin.rootz.global/static/filing/0001104659-20-028925.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"endogenous Cushing&#x2019;s syndrome (&#x201C;CS&#x201D;), a rare endocrine disease characterized by excessive cortisol production from the adrenal glands. As a result of slower than anticipated enrollment in its CS Phase 2 clinical trial, the Company elected to discontinue this trial in August 2019, suspend development of nevanimibe for the treatment of CS, and focus its resources on other programs","filed_date":"2019-11-13","accession":"0001558370-19-010887","full_text":"https://origin.rootz.global/static/filing/0001558370-19-010887.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"eport on Form 10Q and in our Annual Report on Form 10-K for the year ended December 31, 2018. The occurrence of any of the events or circumstances described below or other adverse events could have a material adverse effect on our business, results of operations and financial condition and could cause the trading price of our common stock to decline. Additional risks or uncertainties not presently known to us or that we","filed_date":"2019-11-13","accession":"0001558370-19-010887","full_text":"https://origin.rootz.global/static/filing/0001558370-19-010887.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"endogenous Cushing&#x2019;s syndrome (&#x201C;CS&#x201D;), a rare endocrine disease characterized by excessive cortisol production from the adrenal glands. As a result of slower than anticipated enrollment in its CS Phase 2 clinical trial, the Company elected to discontinue this trial in August 2019, suspend development of nevanimibe for the treatment of CS, and focus its resources on other programs","filed_date":"2019-08-12","accession":"0001558370-19-007932","full_text":"https://origin.rootz.global/static/filing/0001558370-19-007932.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"eport on Form 10Q and in our Annual Report on Form 10-K for the year ended December 31, 2018. The occurrence of any of the events or circumstances described below or other adverse events could have a material adverse effect on our business, results of operations and financial condition and could cause the trading price of our common stock to decline. Additional risks or uncertainties not presently known to us or that we","filed_date":"2019-08-12","accession":"0001558370-19-007932","full_text":"https://origin.rootz.global/static/filing/0001558370-19-007932.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"eport on Form 10Q and in our Annual Report on Form 10-K for the year ended December 31, 2018. The occurrence of any of the events or circumstances described below or other adverse events could have a material adverse effect on our business, results of operations and financial condition and could cause the trading price of our common stock to decline. Additional risks or uncertainties not presently known to us or that we","filed_date":"2019-05-15","accession":"0001558370-19-005038","full_text":"https://origin.rootz.global/static/filing/0001558370-19-005038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TPST","company":"Tempest Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":42,"context":"nst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019. 3.To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement. 4.To approve the Company's 2019 Equity Incentive Plan. 5.To approve the Company's 2019 Employee Stock Purchase Plan. 6.To conduct any other busines","filed_date":"2019-04-29","accession":"0001047469-19-002693","full_text":"https://origin.rootz.global/static/filing/0001047469-19-002693.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"6af3308ca476589d9f9652e10401e2db980c83ba58da001ac97ba5e1e236c3b6","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"ac5c82d1a94759b04984efb3543efb793813a2ed81529aa00e2f2e2adc5cf981","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":7,"hourly_limit":500,"remaining":493,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}